Catalyst Dossier · compiled by CeliA 🧫

LeonaBio, Inc. (LONA)

Biological Products, (No Diagnostic Substances) · market cap $10M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

LeonaBio, Inc. (LONA) is a clinical-stage biotech with a single disclosed asset, ATH-1017, currently in Phase 3 trials for Alzheimer's Disease. The company carries a $71M market cap against $32.8M in cash, implying a roughly $38M enterprise value, with a critical ~4.7-month cash runway that makes near-term financing essentially non-negotiable.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ATH-1017	Phase 3	Alzheimer Disease

Price & technical context

3-month

-19.8%

6-month

+64.7%

12-month

+106.9%

52-wk range

$3.60–$11.68

vs 50-day MA

-9.4%

vs 200-day MA

+8.1%

Realized vol

96.8%

Max drawdown

-93.3%

Daily closes through 2026-08-04. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for LONA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.